All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1100+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Pfizer lands broader FDA approval for RSV vaccine
Vaccine, respiratory syncytial virus - Read more

Johnson & Johnson’s Darzalex scores European Commission approval as part of multiple myeloma regimen
Monoclonal antibody, multiple myeloma, cancer - Read more

RaQualia Pharma’s sublicensee Shandong Luoxin Pharmaceutical Group receives Chinese NMPA approval for H. pylori adjunctive therapy
Small molecule, H. pylori infection, gastroesophageal reflux disease - Read more

DBV Technologies receives accelerated approval guidance from FDA for Viaskin peanut patch
Medical device, peanut allergy - Read more

THE GOOD
Business Development

Eccogene nabs $60M milestone payment from AstraZeneca after first Ph2b patient dosing
Small molecule, obesity, type 2 diabetes - Read more

SIGA Technologies in-licenses preclinical mAb library from Vanderbilt University
Monoclonal antibody, smallpox, mpox (monkeypox) - Read more

NImmune buys Asia development, commercialization rights to omilancor, originating from LianBio wind-down earlier this year
Small molecule, ulcerative colitis, Crohn’s disease - Read more

Duhn Therapeutics buys development, commercialization rights to DHN198 (OH-2714) from OM Pharma for undisclosed upfront, “double-digit” royalties, $116.5M biobucks
Small molecule, solid tumor, cancer - Read more

THE GOOD
Clinical Trials

Alkeus Pharmaceuticals’ reports “significant trend” in reducing GA lesions with gildeuretinol
Small molecule, geographic atrophy - Read more

Zhaoke Ophthalmology touts pair of positive Ph3 results, myopia progression control with NVK002
Small molecule, myopia - Read more

Calluna Pharma’s CAL101 mAb demonstrates favourable safety, pharmacokinetic (PK) and immunogenicity profile in Ph1
Monoclonal antibody, idiopathic pulmonary fibrosis, systemic sclerosis - Read more

Hansoh Pharma showcases positive Ph3 results for aumolertinib in lung cancer
Small molecule, lung cancer - Read more

Revolution Medicine touts updated results from RMC-6236 Ph1, "durable antitumour activity"
Small molecule, pancreatic cancer - Read more

PRESENTED BY BIO-RESEARCH.AI
Smarter, More Accessible DB Service Accelerates Future Drug Development!

Our cutting-edge AI technology processes pharma text data and builds our Deal DB, which currently includes over 25,000 global pharma-biotech deals (and growing).

Each deal provides details such as R&R, financial terms, drug profiles, clinical trial status, and even contracts.

With this DB, you can generate deal comparison tables with one click, calculate deal terms, track target trends, monitor big pharma's focus, and use keyword-based AI auto trackers. Save valuable resources with a cost-effective database.

Talk to our sales team and try out our service. Don’t miss this limited-time offer!

⬇️ More Good News ⬇️

THE GOOD
Earnings & Finances

Thermo Fisher has high hopes for 2025 revenue
Instrumentation, services - Read more [Paywall]

THE GOOD
Fundraises

4Tissue €2M ($2.2M) Seed Raise
Tissue engineering, bio-interactive hydrogels - Read more

Alpha-9 Oncology $175M Series C
Radiopharm, melanoma, cancer, radiodiagnostics - Read more

Dimension plans $500M follow-up fund
Venture capital, life science digitization - Read more [Paywall]

March Biosciences $24.8M Series A
Cell therapy, T-cell lymphoma, CAR-T - Read more

Avenue Biosciences $2.5M Seed raise
Platform technology, protein drug discovery - Read more

Ikarovec £5M ($6.5M) Seed extension
Gene therapy, geographic atropy, wet age-related macular degeneration - Read more

THE GOOD
Mergers & Acquisitions

Merck & Co. buys Modifi Biosciences for $30M upfront, $1.3B biobucks
Small molecule, glioblastoma, cancer - Read more

Ocuphire, Opus Genetics retinal gene therapy-focused merger
Gene therapy, inherited retinal diseases, presbyopia - Read more

Lumos Pharma goes private via merger with Double Point Ventures through common stock purchase
Small molecule, pediatric growth hormone deficiency - Read more

THE GOOD
Partnerships

Evotec, Bristol Myers Squibb molecular-glue partnership expands beyond oncology, $50M milestone payment to Evotec
Molecular glue degrader, oncology, cancer - Read more

ABL Bio, IntoCell partner to develop novel ADCs
Antibody-drug conjugate, cancer, drug development - Read more

THE GOOD
Public Health

Harvard University updates climate toolkit for healthcare workers
Climate change, healthcare frontlines - Read more

THE GOOD
Strategic Plans

Roche not bothered by Vabysmo biosimilars, bullish on continued momentum
Monoclonal antibody, wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Eli Lilly’s Kisunla has “relatively little benefit”, too costly for NHS according to UK’s NICE
Monoclonal antibody, Alzheimer’s disease - Read more

THE BAD
Business Development

Legend Biotech removes Genscript Biotech as majority shareholder amid Biosecure Act tensions
Biosecure Act, CDMO, geopolitics - Read more

THE BAD
Clinical Trials

Alto Neuroscience’s ALTO-100 flunks Ph2b, shares crater
Small molecule, major depressive disorder - Read more

THE BAD
Layoffs

Pfizer to cut 75 more roles at North Carolina site, related to failed DMD gene therapy asset fordadistrogene movaparvovec
Gene therapy, Duchenne muscular dystropy - Read more

THE BAD
Mergers & Acquisitions

Roche CEO voices doubt about upcoming Novo Holdings’ Catalent acquisition, risk of reduced available CMO capacity “problem for other smaller players“
CDMO, manufacturing capacity - Read more 

THE BAD
Patient Access

Novo Nordisk takes alternative approach to stop semaglutide compounders, presses FDA to include semaglutide on “Demonstrable Difficulties for Compounding“ list
GLP-1, obesity, compounding pharmacy - Read more

THE BAD
Strategic Plans

Roche cuts cough candidate RG6341 as part of wider pipeline prioritization
Small molecule, cough - Read more

THE UGLY
No Ugly News today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here